API | matuzumab

matuzumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
matuzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Epidermal growth factor receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

emd72000 | emd 72000 | emd-72000 | matuzumab

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Esophageal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue